If using the triplet AMPLIFY regimen with ven/acala/obin upfront, what do you then plan to use in 2nd line treatment of CLL?  

If using AVO upfront, I would give AVO, AV, VO, or a continuous BTKi as second-line therapy depending on duration of remission, new comorbidities, and how well they tolerated in initial therapy.

For patients who achieve a favorable response that lasts >1 year (or so, this is a ballpark estimate that may shift with more data), I would be very comfortable re-treating with a covalent BTKi (preferably after screening for BTK resistance mutations by NGS where available - with note of caution ...